The Spanish Association of Orphan and Ultra-Orphan Drug Laboratories(AELMHU) today presents the results of its Annual Report on Access to Orphan Drugs for 2024, which every year provides information on the situation of these drugs in Europe and their availability for patients in Spain.

The report analyzes the data on orphan drugs based on different European and Spanish public sources as of December 31, 2024, taking into account the evolution of the indicators.

According to the analysis, the situation in Europe has shown a positive evolution, with 25 new drugs with orphan designation and trade name, 6 more than in 2023. In addition, 17 drugs obtained marketing authorization in the European Union from the European Medicines Agency (EMA), improving the number of authorized products by 5 points over the previous year.